In pursuit of novel, selective small molecules, GlaxoSmithKline (GSK) has signed a deal with Exscientia to utilise the latter’s artificial intelligence (AI)-driven drug discovery platform to develop up to 10 new drugs for undisclosed disease-related targets which are selected by GSK. Exscientia will receive research funding and will receive £33 M (US$43 M) if all 10 programmes are advanced. Exscientia aims to use its technology to reduce the number of compounds required for synthesis and assay in order to achieve lead and candidate compound goals, therefore accelerating the drug discovery process.